Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Dyax, ImClone deal

The companies extended by four years a 2003 deal that granted IMCL a non-exclusive license to DYAX's antibody

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE